ResMed Q1 FY23 revenue $950.3M (+5% YoY, +9% CC); GAAP EPS $1.43, non-GAAP $1.51

RESMED INC

2023-Q1 EPS reported $1.43 revenue$950,294,000

Revenue $950.3M, up 5% YoY (9% constant currency); Americas (ex-SaaS) revenue up 18%.
GAAP operating profit $275.7M (+5%), non-GAAP operating profit $290.8M (+4%).
GAAP diluted EPS $1.43 vs $1.39; non-GAAP diluted EPS $1.51 flat YoY.
Board declared quarterly dividend $0.44/share, payable Dec 15, 2022, record Nov 10.
Acquired mementor (German digital sleep medicine); opened new R&D facility in Ireland.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.